Isoprenaline Hcl Macure

Isoprenaline Hydrochloride, the active ingredient in Isoprenaline Hcl Macure, is a non‑selective beta‑adrenergic agonist presented as an injectable solution for intravenous administration. It is used to increase heart rate and contractility in symptomatic bradycardia, heart block, cardiogenic shock, and to relax bronchial smooth muscle in asthma or bronchospasm.

GNH USA supplies Isoprenaline Hcl Macure as a licensed, GMP‑and GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under regulated quality standards.

Isoprenaline Hydrochloride acts on beta‑adrenergic receptors to provide cardiac stimulation and bronchodilation.

- Symptomatic bradycardia: increases heart rate to alleviate slow heart rhythms. - Heart block: improves atrioventricular conduction and cardiac output. - Cardiogenic shock: enhances myocardial contractility and cardiac output during low‑output states. - Asthma and bronchospasm: relaxes bronchial smooth muscle to improve airflow.

Isoprenaline may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Tachycardia: rapid heart rate. - Palpitations: awareness of heartbeat. - Tremor: fine muscle shaking. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Arrhythmias: potentially life‑threatening irregular heart rhythms. - Myocardial ischemia: reduced blood flow to heart muscle. - Severe bronchospasm: paradoxical worsening of airway constriction.

Use of Isoprenaline requires careful clinical monitoring.

- Cardiac monitoring: observe heart rate and rhythm during infusion. - Hypotension risk: monitor blood pressure, especially in patients with pre‑existing low pressure. - Thyroid disease: use cautiously in hyperthyroid patients. - Diabetes: beta‑agonist may affect glucose levels. - Concomitant MAO inhibitors: increased risk of hypertensive crisis. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Isoprenaline can interact with several drug classes, requiring attention to avoid reduced efficacy or heightened toxicity.

Major Interactions (Avoid): - Beta‑blockers: antagonize therapeutic effect, may precipitate severe bradycardia. - Monoamine oxidase inhibitors (MAOIs): may cause hypertensive episodes. - Digitalis glycosides: increased risk of arrhythmias.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate electrolyte disturbances affecting cardiac response. - Anticholinergic agents: may blunt bronchodilatory effect. - CYP450 inhibitors: potential alteration of drug clearance, though data are limited.